Loading...
Home2019-02-22T21:28:21+00:00

Unprecedented Insights

ImaginAb is an emerging immune-oncology imaging company developing a pipeline of novel products that give physicians unprecedented insights into the patient’s health—enabling better patient selection and treatment monitoring for immuno-oncology therapies and other drugs.

Harnessing the specificity of monoclonal antibodies, ImaginAb designs and engineers small, highly targeted proteins known as minibodies that image important molecular targets using standard Positron Emission Tomography (PET).

Our imaging tools help physicians answer important clinical questions, improving the path of care and ultimately helping patients live longer, healthier lives.

We image critical targets in immuno-oncology to help patients and their doctors make better-informed treatment decisions.

Our approach
100%

ACCURACY

100%

INNOVATION

100%

CLARITY

100%

BETTER DATA

Read latest publications

Can in vivo imaging deliver the full potential of immunotherapy?

In the quest to control cancer we now face the challenge of translating our increasing insights into the cancer-immunity cycle into more effective immune therapies. In vivo imaging in preclinical models has been instrumental in understanding the complex interactions of cancer and the immune system. The great task now lies in imaging immune responses in real cancer patients in a safe and non-invasive manner, to realise the full potential of immunotherapy in the clinic.